Trial reportKidney international2015
Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
Trial report in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Pharmacological interventions for heart failure in people with chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Niacin for primary and secondary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2017 · on this mapPooled it
- Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial).The American journal of cardiology · 2023Trial
- Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease.Lipids in health and disease · 2026Review
- Review
- Lipoprotein Subfractions Predict All-cause and Cardiovascular Mortality in CKD Patients Undergoing Hemodialysis: A Prospective Cohort Study Based on NMR Metabolomics.Phenomics (Cham, Switzerland) · 2025Article
- Targeting cardiovascular and metabolic risk modification in end stage renal disease (ESRD): a randomized controlled clinical trial on niacin's effects on lipoprotein(a) and biochemical markers in hemodialysis patients.Frontiers in medicine · 2025Article
- The Association of Niacin Use with Kidney Outcomes and Mortality.American journal of nephrology · 2025Article
- Article
- Dietary niacin intake and mortality among chronic kidney disease patients.Frontiers in nutrition · 2024Article
- Association of dietary niacin intake with all-cause and cardiovascular mortality of adult patients with chronic kidney disease in the United States: results from NHANES 1999-2018.Frontiers in nutrition · 2024Article
- Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis.Nutrition & metabolism · 2022Article
- Regulation of NADMetabolism: clinical and experimental · 2022Review
- The causal effects of serum lipids and apolipoproteins on kidney function: multivariable and bidirectional Mendelian-randomization analyses.International journal of epidemiology · 2021Article
- Effect of pravastatin on erythrocyte membrane fatty acid contents in patients with chronic kidney disease.Kidney research and clinical practice · 2021Article
- Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.Cardiovascular drugs and therapy · 2021Review
- Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis.Diabetology & metabolic syndrome · 2021Article
- Bioactive Compounds for the Management of Hypertriglyceridemia: Evidence From Clinical Trials and Putative Action Targets.Frontiers in nutrition · 2020Review
- Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
- The effect of chronic kidney disease on lipid metabolism.International urology and nephrology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Chronic kidney disease (CKD) in patients is strongly associated with cardiovascular morbidity and mortality, and prevalent abnormal lipid metabolism. The AIM-HIGH trial examined the benefits of adding extended-release niacin (ERN) to simvastatin in patients with established coronary heart disease. Here we conducted a post hoc analysis of the AIM-HIGH trial examining whether participants derived cardiovascular or renal benefits when stratified by renal function. Of 3414 participants, 505 had stage 3 CKD at baseline. Among the CKD subset, demographics and cardiovascular disease (CVD) risk factors were well balanced in the ERN and placebo arms. Compared with placebo, CKD participants receiving ERN had a significant decrease in triglycerides by a median of 59.0 mg/dl, and high-density lipoprotein cholesterol significantly increased by a mean of 11.3 mg/dl over a mean follow-up of 3 years. CVD events were similar between CKD participants in both arms. However, all-cause mortality was significantly higher in the ERN group (hazard ratio of 1.73). Mean change in eGFR among ERN-treated CKD participants was not significantly different between study arms. Thus, among AIM-HIGH participants with CKD, the addition of ERN to simvastatin for secondary prevention of CVD improved triglyceride and high-density lipoprotein-cholesterol concentrations but did not improve cardiovascular outcomes or kidney function, and was associated with higher all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.